Darzalex' 2020 sales reach prognosis peak
Johnson & Johnson's sales of the Genmab-developed drug Darzalex has continued its growth in Q4, and so, the drug has reached the upper end of expected sales.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Sales relating to the original version of the cancer drug Darzalex and the new version Darzalex Faspro has maintained its growth with one minor setback at the beginning of the year due to Covid-19, which Genmab announces in a press statement after seller Johnson & Johnson, which is responsible for the drug, has published the report.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
